Lower cognitive performance in healthy G2019S LRRK2 mutation carriers

Avner Thaler; Anat Mirelman; Tanya Gurevich; Ely Simon; Avi Orr-Urtreger; Karen Marder; Susan Bressman; Nir Giladi

doi:https://doi.org/10.1212/WNL.0b013e3182684646

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers

Avner Thaler, Anat Mirelman, Tanya Gurevich, Ely Simon, Avi Orr-Urtreger, Karen Marder, Susan Bressman, Nir Giladi

Tel Aviv University, Ben-Gurion University of the Negev

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene. Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale. Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007). Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.

Original language	English
Pages (from-to)	1027-1032
Number of pages	6
Journal	Neurology
Volume	79
Issue number	10
DOIs	https://doi.org/10.1212/WNL.0b013e3182684646
State	Published - 4 Sep 2012

All Science Journal Classification (ASJC) codes

Clinical Neurology

Access to Document

https://doi.org/10.1212/WNL.0b013e3182684646

Cite this

@article{2aa18828318341858d92d3bd20a513e2,

title = "Lower cognitive performance in healthy G2019S LRRK2 mutation carriers",

abstract = "Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene. Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale. Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007). Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.",

author = "Avner Thaler and Anat Mirelman and Tanya Gurevich and Ely Simon and Avi Orr-Urtreger and Karen Marder and Susan Bressman and Nir Giladi",

note = "Funding Information: Study funding: Supported by grants from the Tel Aviv Sourasky Medical Center Grant of Excellence, Khan Foundation, Israel Science Foundation Heritage Legacy, the Michael J. Fox Foundation for Parkinson's Research, and the UMC ST Radboud, Nijmegen, the Netherlands. The LRRK2 Ashkenazi Jewish Consortium is funded by the Michael J. Fox Foundation, New York, New York.",

year = "2012",

month = sep,

day = "4",

doi = "https://doi.org/10.1212/WNL.0b013e3182684646",

language = "الإنجليزيّة",

volume = "79",

pages = "1027--1032",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Lower cognitive performance in healthy G2019S LRRK2 mutation carriers

AU - Thaler, Avner

AU - Mirelman, Anat

AU - Gurevich, Tanya

AU - Simon, Ely

AU - Orr-Urtreger, Avi

AU - Marder, Karen

AU - Bressman, Susan

AU - Giladi, Nir

N1 - Funding Information: Study funding: Supported by grants from the Tel Aviv Sourasky Medical Center Grant of Excellence, Khan Foundation, Israel Science Foundation Heritage Legacy, the Michael J. Fox Foundation for Parkinson's Research, and the UMC ST Radboud, Nijmegen, the Netherlands. The LRRK2 Ashkenazi Jewish Consortium is funded by the Michael J. Fox Foundation, New York, New York.

PY - 2012/9/4

Y1 - 2012/9/4

N2 - Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene. Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale. Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007). Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.

AB - Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene. Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale. Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007). Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.

UR - http://www.scopus.com/inward/record.url?scp=84866091335&partnerID=8YFLogxK

U2 - https://doi.org/10.1212/WNL.0b013e3182684646

DO - https://doi.org/10.1212/WNL.0b013e3182684646

M3 - مقالة

C2 - 22914834

SN - 0028-3878

VL - 79

SP - 1027

EP - 1032

JO - Neurology

JF - Neurology

IS - 10

ER -

Lower cognitive performance in healthy G2019S LRRK2 mutation carriers

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this